TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2686393

Group type: COMPARATOR
Intervention: Doxorubicin (D) alone (60 mg/m2, observation after 500 mg/m2)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Doxorubicin (D) combined with Vincristine (V) and Mitomycin C (M) (D: 50 mg/m2, V: 1 mg/m2, M: 10 mg/m2, given every other cycle)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Vincristine (V) and Mitomycin C (M) following Doxorubicin (D) alone
Number of subjects: 185

Group type: COMPARATOR
Intervention: Doxorubicin (D) alone
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Doxorubicin (D) combined with Vincristine (V) and Mitomycin C (M)
Number of subjects: 185
Study: 29940261

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 28623892

Group type: EXPERIMENTAL
Intervention: Home-based social worker stroke case management (SWSCM) program
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combination of SWSCM program plus access to an online information and support resource (MISTT website)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 26115976

Group type: EXPERIMENTAL
Intervention: carboplatin/docetaxel + celecoxib
Number of subjects: 196

Group type: COMPARATOR
Intervention: carboplatin/docetaxel
Number of subjects: 196
Study: 23228436

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Therapy (MET/CBT)+Parent Management Training+Contingency Management (CM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: MET/CBT+Parent Drug Education (attention control)
Number of subjects: 68
Study: 21727105

Group type: EXPERIMENTAL
Intervention: Obesogenic control scale
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Obesogenic risk scale
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Interaction between control and risk scales
Number of subjects: 1685
Study: 19727022

Group type: EXPERIMENTAL
Intervention: Protease supplementation (5.83 g daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Protease supplementation
Number of subjects: 29
Study: 16919574

Group type: EXPERIMENTAL
Intervention: Mental stress testing (technetium 99m methoxyisobutylisonitrile myocardial scintigraphy)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physical or mental stress
Number of subjects: 16
Study: 15273899

Group type: EXPERIMENTAL
Intervention: Rear-wheel position I
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rear-wheel position II
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rear-wheel position I and II
Number of subjects: 12
Study: 11724457

Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acid (PUFA) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9203116

Group type: EXPERIMENTAL
Intervention: Form 90 (structured interview for assessing alcohol treatment outcomes)
Number of subjects: 178
Study: 8356998

Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000-2,000 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac (100-200 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Piroxicam (10-20 mg/day)
Number of subjects: 100
Study: 3112999

Group type: EXPERIMENTAL
Intervention: Experimental nursing home settings
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional long-stay wards
Number of subjects: 41
Study: 29888715

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Different protocol of ozone therapy group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ozone therapy group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 26865200

Group type: EXPERIMENTAL
Intervention: Thiazide prescription
Number of subjects: 7582

Group type: EXPERIMENTAL
Intervention: Single agent prescription
Number of subjects: 7582

Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 7582

Group type: EXPERIMENTAL
Intervention: Kidney function
Number of subjects: 7582
Study: 24285366

Group type: EXPERIMENTAL
Intervention: Anterior referencing (AR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterior referencing (PR)
Number of subjects: 100
Study: 22843306

Group type: EXPERIMENTAL
Intervention: Group V: Anesthesia induced with midazolam, remifentanil, propofol, and vecuronium; maintained with continuous infusion of propofol and remifentanil.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group I: Anesthesia induced with midazolam, fentanyl, propofol, and vecuronium; maintained with inhaled isoflurane and intravenous bonus of fentanyl.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C: Anesthesia induced as in group I; maintained with isoflurane inhalation combined with propofol-remifentanil infusion.
Number of subjects: 60
Study: 21051293

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Plasmapheresis (PP)
Number of subjects: 28
Study: 17029543

Group type: EXPERIMENTAL
Intervention: Group 2, Fuji Ortho LC without acid conditioning
Number of subjects: 15

Group type: COMPARATOR
Intervention: Group 1, phosphoric acid + Fuji Ortho LC
Number of subjects: 15
Study: 15740824

Group type: EXPERIMENTAL
Intervention: Estratab plus Prometrium
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Estratest
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Estratab plus Provera
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: COMPARATOR
Intervention: Estratab (primarily estrone)
Number of subjects: 89
Study: 12850363

Group type: EXPERIMENTAL
Intervention: Maternal 9-valent PCV immunization
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 10418709

Group type: EXPERIMENTAL
Intervention: In vivo prompt gamma neutron activation analysis using a 252Cf neutron source, 40 min duration, mean whole-body equivalent dose of 0.25 mSv
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Solid phantom measurements for long-term stability
Number of subjects: 13
Study: 7730003

Group type: EXPERIMENTAL
Intervention: Health instruction provided by student nurses
Number of subjects: 285
Study: 2203303

Group type: EXPERIMENTAL
Intervention: Cefepime (62.5, 125, 250, 500, 1,000, or 2,000 mg as a 30‐min intravenous infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefepime (250 to 2,000 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 24
Study: 6791201

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) with a large, fatty meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) leading to Nortriptyline (NT) production
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 6
Study: 30679095

Group type: EXPERIMENTAL
Intervention: Oral insulin 338 (I338)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous insulin glargine (IGlar)
Number of subjects: 50
Study: 29930798

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment, administered two times a week for two weeks.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 200
Study: 27349944

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 79
Study: 24335157

Group type: EXPERIMENTAL
Intervention: ICDAS II + LAA
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nyvad
Number of subjects: 140
Study: 22110048

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 30
Study: 19494215

Group type: EXPERIMENTAL
Intervention: TMC207 (400 mg daily for 2 weeks, followed by 200 mg three times a week for 6 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17484523

Group type: EXPERIMENTAL
Intervention: Bach's Magnificat during physiotherapy treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (physiotherapy only)
Number of subjects: 40
Study: 15064016

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO), n = 39, given orally at a dose of 0.45 g/m(2) 4 hours prior to radiation treatment and during brachytherapy (40Gy)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (P), n = 34, given in addition to radiotherapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 73
Study: 11430843

Group type: EXPERIMENTAL
Intervention: Innovative therapy using approved drugs for unapproved purposes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active treatments in controlled trials
Number of subjects: 0
Study: 9535316

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 376
Study: 7648803

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30 mg d‐1 for initial 3 months)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Regular clinic visits
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Behavioural group therapy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combined home and clinic visits
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (58 patients)
Number of subjects: 159
Study: 2501593

Group type: EXPERIMENTAL
Intervention: DFMO (D,L-alpha-difluoromethylornithine) administered orally at a dose of 1.7 g/sq.m. t.i.d.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional chemotherapy without DFMO
Number of subjects: 38
Study: 778456

Group type: EXPERIMENTAL
Intervention: Intravenous fructose (1000 cc of 10% fructose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous glucose (10% glucose)
Number of subjects: 20
Study: 30733167

Group type: EXPERIMENTAL
Intervention: Web-based cognitive assessments
Number of subjects: 104
Study: 28438539

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg/d) 3 d/wk for 12 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study: 26224129

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 23474153

Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg BID for 12 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 22379922

Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Number of subjects: 0
Study: 20085679

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 400 mg three times daily from 36 weeks' gestation
Number of subjects: 27
Study: 17699214

Group type: COMPARATOR
Intervention: Ramipril + spironolactone placebo + irbesartan placebo
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ramipril + irbesartan + spironolactone placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ramipril + irbesartan placebo + spironolactone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ramipril + irbesartan + spironolactone
Number of subjects: 41
Study: 15657468

Group type: EXPERIMENTAL
Intervention: HGlu (glucose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HMal (maltose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MalMix (sucrose, maltose, and maltodextrin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Plac (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MalMix
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (HGlu, HMal, MalMix)
Number of subjects: 10
Study: 11350782

Group type: EXPERIMENTAL
Intervention: Insulin infusion to achieve moderate (approximately 75 pmol/l) and high (approximately 150 pmol/l) physiological insulin levels during hyperinsulinemic‐hyperglycemic clamps.
Number of subjects: 28
Study: 9266778

Group type: EXPERIMENTAL
Intervention: Amlodipine therapy for 10 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control test
Number of subjects: 7
Study: 7743568

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Caudal anaesthesia (CA)
Number of subjects: 202
Study: 2352468

Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl 0.001%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.001% mixed with bupivacaine 0.1%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl 0.0005%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.0005% mixed with bupivacaine 0.1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (fentanyl 0.0005%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (fentanyl 0.0005% mixed with bupivacaine 0.1%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 6163292

Group type: EXPERIMENTAL
Intervention: Candle-jar system for direct inoculation in culture diagnosis of gonorrhoea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional system using Stuart transportation medium and inoculation in the laboratory
Number of subjects: 0
Study: 30600490

Group type: EXPERIMENTAL
Intervention: Mixed Exercise Program (MEXP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 14
Study: 28078530

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster, applied as one or three simultaneous plasters
Number of subjects: 0
Study: 26095558

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SP)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 4-port laparoscopic cholecystectomy (FP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Follow-up for >1 year
Number of subjects: 110
Study: 23334675

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 25 mg/day
Number of subjects: 699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study: 21834921

Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 fatty acids supplementation (3 capsules daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo containing medium-chain triglycerides
Number of subjects: 138
Study: 19567409

Group type: EXPERIMENTAL
Intervention: Piboserod 80 mg for 24 weeks
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 17352805

Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage (for 4 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Early surgical treatment (within one week)
Number of subjects: 210
Study: 15476525

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11493488

Group type: EXPERIMENTAL
Intervention: Desflurane at 1 MAC (7.4%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC (10.8%)
Number of subjects: 8
Study: 8790024

Group type: EXPERIMENTAL
Intervention: Xemilofiban (5, 10, 15, or 20 mg) administered 8 to 18 hours after abciximab termination
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (ticlopidine) administered 8 to 18 hours after abciximab termination
Number of subjects: 74
Study: 1734217

Group type: EXPERIMENTAL
Intervention: Idarubicin (12.5 mg/m2/dose) in combination with vincristine, prednisone, and L-asparaginase (VPLI)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Daunorubicin (30 mg/m2) in combination with vincristine, prednisone, and L-asparaginase (VPLD)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Daunorubicin
Number of subjects: 85
Study: 6380903

Group type: EXPERIMENTAL
Intervention: Schering gentamicin 1 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Invenex gentamicin 1 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Schering gentamicin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Invenex gentamicin
Number of subjects: 10
Study: 30171400

Group type: EXPERIMENTAL
Intervention: Bonding application (BD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Teethmate desensitizer (TM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser application (LS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No surface treatment (control, C)
Number of subjects: 60
Study: 28504468

Group type: EXPERIMENTAL
Intervention: Potentiated zinc pyrithione (ZPT) antidandruff shampoo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo cosmetic shampoo
Number of subjects: 24
Study: 27015634

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids 2.4 g
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24958795

Group type: EXPERIMENTAL
Intervention: Small group tutorial
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interactive Developmental Teaching (IDT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (didactic lecture followed by self-study with online resources)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: IDT and small groups
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: IDT group
Number of subjects: 114
Study: 22381603

Group type: EXPERIMENTAL
Intervention: 500 mg of intramuscular 17P after tocolysis, repeated semiweekly until 36 weeks or preterm delivery.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no 17P treatment).
Number of subjects: 188

Group type: COMPARATOR
Intervention: 17P treatment and Control group.
Number of subjects: 188
Study: 19534374

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% wound infiltration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ketorolac incisional infiltration 60mg
Number of subjects: 70
Study: 17413559

Group type: EXPERIMENTAL
Intervention: Molecular Adsorbents Recirculating System (MARS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prometheus
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 8

Group type: COMPARATOR
Intervention: MARS and Prometheus
Number of subjects: 8
Study: 16329019

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 34

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 34
Study: 12134308

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative or surgical treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials with random assignation
Number of subjects: 0
Study: 10457699

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (untreated eye)
Number of subjects: 22
Study: 7818114

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 76
Study: 2157988

Group type: EXPERIMENTAL
Intervention: Rheumajecta and Vasolastine (R and V)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7021410

Group type: EXPERIMENTAL
Intervention: Domiciliary treatment with isoniazid and PAS for one year in 3 treatment towns
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Domiciliary treatment with isoniazid alone for one year in 3 treatment towns
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Control group with no special facilities for diagnosis or treatment
Number of subjects: 1482
Study: 30273086

Group type: EXPERIMENTAL
Intervention: Mind-body intervention as an adjunct to SUD treatment
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 217
Study: 28770298

Group type: EXPERIMENTAL
Intervention: TKA without removal of the lateral posterior femoral cartilage (Group 1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: TKA with removal of the lateral posterior femoral cartilage (Group 2)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 106
Study: 25721879

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention, 60-minute sessions, five times a week for 1 year
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 24685737

Group type: EXPERIMENTAL
Intervention: Continuous care model applied for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 90
Study: 23051611

Group type: EXPERIMENTAL
Intervention: Recall letter sent to parents of 438 eligible children
Number of subjects: 878

Group type: COMPARATOR
Intervention: No recall letter sent (control group)
Number of subjects: 878
Study: 20027849

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus resistance training (WBV+RT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 51
Study: 18074914

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and mucosal plication (RAMP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ligature and excision procedure (LEP)
Number of subjects: 46
Study: 15363817

Group type: EXPERIMENTAL
Intervention: Treatment (median 3 years)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pretreatment levels in patients with hypertension
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MMP‐9 levels
Number of subjects: 96
Study: 11481349

Group type: EXPERIMENTAL
Intervention: marimastat 5 mg bid
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: marimastat 10 mg bid
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: marimastat 25 mg bid
Number of subjects: 414

Group type: COMPARATOR
Intervention: gemcitabine 1,000 mg/m2
Number of subjects: 414
Study: 9669426

Group type: EXPERIMENTAL
Intervention: Allopurinol (a xanthine oxidase inhibitor)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39